Helix Biopharma Corp.
HBP.TO
TSX
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.95% | -24.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.09% | -36.19% | |||
| Operating Income | 4.09% | 36.19% | |||
| Income Before Tax | -5.05% | 36.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.05% | 36.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.05% | 36.34% | |||
| EBIT | 4.09% | 36.19% | |||
| EBITDA | 4.21% | 36.12% | |||
| EPS Basic | 2.04% | 52.20% | |||
| Normalized Basic EPS | 1.64% | 52.34% | |||
| EPS Diluted | 2.04% | 52.20% | |||
| Normalized Diluted EPS | 1.64% | 52.34% | |||
| Average Basic Shares Outstanding | 7.02% | 33.67% | |||
| Average Diluted Shares Outstanding | 7.02% | 33.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||